绝经激素治疗新进展

摘要/Abstract

摘要：

2002年美国妇女健康干预（Women’s Health Initiative,WHI）的发表使绝经激素治疗进入了一个低谷。近10年来该领域取得了重大进展，目前的观点已经有很大的不同。该文在具体介绍WHI 研究后，着重介绍了该领域10年来的最重要研究，包括WHI再分析、丹麦的DOPS研究、欧洲的EURAS-HRT研究等，突出了这10年来最重要的进展为“窗口期”理论和孕激素选择。最后介绍了2013年关于绝经激素治疗（menopausal hormone therapy，MHT）的国际共识要点。

关键词: 绝经激素治疗, 激素补充治疗, 窗口期理论, 孕激素

Abstract:

Abstract：Publication of the first results from the Women’s Health Initiative (WHI) trial in 2002 made menopausal management fall to peak negative sentiment. Over the past decade significant progress have been made in this area. The opinions about menopausal management are distinguished different from those around 2002. After discussion about design and limitations of WHI, the most important studies in the recent decade, e.g. reanalysis of WHI, Danish Osteoporosis Prevention Study and European active surveillance study of women taking HRT were detailed introduced. We emphasized that "opportunity window" theory and progestogens effects were the most important progress in the past decade. At the end of this article key points from international consensus about menopausal hormone therapy in 2013 were listed.

Key words: menopausal hormone therapy； hormone replacement therapy；“opportunity window&rdquo, theory； progestogen

中图分类号:

R711.75

陈蓉. 绝经激素治疗新进展[J]. 中国实用妇科与产科杂志.

CHEN Rong. . Progress in postmenopausal hormone therapy.CHEN Rong. [J]. Acta Metallurgica Sinica.

参考文献



[1］ Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health[J]. Climacteric，2013,16:316-337.

[2］ Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progesterone in healthy post- menopausal women[J]. JAMA, 2002,288:321-333.

[3］ Stefanick ML, Anderson GL, Margolis KL, et al.Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy[J].JAMA, 2006,295:1647-1657.

[4］ Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone and risk of cardiovascular disease by age and years since menopause[J]. JAMA, 2007,297:1465-1477.

[5］ Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement[J]. J Clin Endocrinol Metab, 2010,95(7 Suppl 1):s1-s66.

[6］ Sturdee DW, Pines A，International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health[J]. Climacteric, 2011,14(3):302 320.

[7］ Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study[J]. Breast Cancer Res Treat, 2008,107(1):103-111.

[8］ Schierbeck LL, Rejnmark L, Landbo C, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial[J]. BMJ, 2012,345:e6409 doi: 10.1136/bmj.e6409 (Published 9 October 2012).

[9］ Dinger JC, Heinemann LA. European active surveillance study of women taking HRT (EURAS-HRT): study protocol [NCT00214903］[J]. BMC Womens Health,2006,17:1.

[10］中华医学会妇产科学分会绝经学组. 绝经过渡期和绝经后期激素补充治疗临床应用指南（2009版）[J]. 中华妇产科杂志，2010,45（8）：635-638.

[11］中华医学会妇产科学分会绝经学组.绝经期管理与激素补充治疗临床应用指南[J].中华妇产科杂志，2013,48(10):

[12］ North American Menopause Society.The 2012 hormone therapy statement of the north american menopause society[J].Menopause, 2012, 19(3):257-271.

[13］ Gompel A, Rozenberg S, Barlow DH. EMAS board members:The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy[J]. Maturitas, 2008, 61(3):227-232. 

[14］ Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy[J].Maturitas, 2013,74(4):391-392.

[1]	张瑶，马颖. 绝经激素治疗与妇科恶性肿瘤[J]. 中国实用妇科与产科杂志, 2020, 36(3): 217-221.
[2]	王艳，任慕兰. 绝经激素治疗与认知[J]. 中国实用妇科与产科杂志, 2020, 36(3): 221-224.
[3]	史惠蓉，李雪茹. 绝经激素治疗与动静脉血栓栓塞性疾病[J]. 中国实用妇科与产科杂志, 2020, 36(3): 224-227.
[4]	曹金翔，吴洁. 早发性卵巢功能不全激素补充治疗利弊评价[J]. 中国实用妇科与产科杂志, 2020, 36(3): 227-230.
[5]	彭红发，闫晓楠. 绝经激素治疗与骨质疏松症[J]. 中国实用妇科与产科杂志, 2020, 36(3): 230-233.
[6]	阮祥燕，张凌燕. 绝经激素治疗与乳腺癌风险[J]. 中国实用妇科与产科杂志, 2020, 36(3): 213-217.
[7]	刘艳华，杨欣. 绝经激素治疗与心血管疾病[J]. 中国实用妇科与产科杂志, 2020, 36(3): 209-212.
[8]	舒宽勇，邓卫平. 绝经激素治疗与绝经相关症状[J]. 中国实用妇科与产科杂志, 2020, 36(3): 206-209.
[9]	陈蓉，彭雅婧. 《中国绝经管理与绝经激素治疗指南（2018）》在临床的实践[J]. 中国实用妇科与产科杂志, 2020, 36(3): 202-205.
[10]	郁琦，林琳. 绝经管理的整体观[J]. 中国实用妇科与产科杂志, 2020, 36(3): 199-201.
[11]	郁琦. 早发性卵巢功能不全诊治进展[J]. 中国实用妇科与产科杂志, 2018, 34(3): 241-242.
[12]	雷小敏，谭新沙. 早发性卵巢功能不全对骨代谢影响[J]. 中国实用妇科与产科杂志, 2018, 34(3): 245-248.
[13]	史惠蓉，李霞. 早发性卵巢功能不全对心血管疾病影响[J]. 中国实用妇科与产科杂志, 2018, 34(3): 248-251.
[14]	王艳，王丽平. 早发性卵巢功能不全对神经功能影响[J]. 中国实用妇科与产科杂志, 2018, 34(3): 251-255.
[15]	唐瑞怡，陈蓉. 早发性卵巢功能不全激素补充治疗[J]. 中国实用妇科与产科杂志, 2018, 34(3): 261-265.